Taken together, these experiments support the potential clinical applicability of GPX4 inhibitors to eradicate quiescent astrocyte-like tumor cells in human GBM by targeting a mitochondrial vulnerability of this persister-like population which is resistant to standard of care anti-proliferative therapies. This evidence concerns the gene GPX4 and glioblastoma.